Compare PRHI & HIND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | PRHI | HIND |
|---|---|---|
| Founded | 2009 | 2017 |
| Country | United States | United States |
| Employees | N/A | 2 |
| Industry | Property-Casualty Insurers | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.7M | 15.2M |
| IPO Year | 2015 | 2016 |
| Metric | PRHI | HIND |
|---|---|---|
| Price | $6.93 | $2.17 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | ★ 7.2K | 6.3K |
| Earning Date | 05-13-2026 | 05-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 64.86 |
| EPS | ★ 1.66 | N/A |
| Revenue | ★ $43,304,000.00 | $319,714.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $3.89 | ★ N/A |
| Revenue Growth | N/A | ★ 24.43 |
| 52 Week Low | $0.48 | $1.75 |
| 52 Week High | $7.95 | $9.56 |
| Indicator | PRHI | HIND |
|---|---|---|
| Relative Strength Index (RSI) | 67.98 | 50.96 |
| Support Level | $0.60 | $1.99 |
| Resistance Level | N/A | $2.35 |
| Average True Range (ATR) | 1.02 | 0.09 |
| MACD | 0.07 | -0.01 |
| Stochastic Oscillator | 100.00 | 31.31 |
Presurance Holdings Inc is an insurance holding company that markets and services product offerings through specialty personal insurance lines of business. Through its personal insurance lines, it offers homeowners insurance and dwelling fire insurance products to individuals in several states. The specialty homeowners insurance product line is comprised of low-value dwelling insurance tailored for owners of lower valued homes, which it offers in Texas, Illinois and Indiana. Through commercial insurance lines, it offers coverage for both commercial property and commercial liability and also offered coverage for commercial automobiles and workers' compensation. Its revenues are derived from premiums earned from insurance operations.
Vyome Holdings Inc is a clinical-stage specialty pharmaceutical company working to treat immune-inflammatory and rare diseases of unmet need with next-generation therapeutic solutions. Its product candidates are: VT-1953, a topical gel that is being developed to treat signs and symptoms of malignant fungating wounds in cancer; VT-1908, a repurposed immune modulator to treat steroid-sparing anterior uveitis; and VB1953, which is being developed to treat moderate to severe acne. Vyome has also commercialized two novel reformulated topical anti-fungal products based on the technology platform of Molecular Replacement Therapeutics (MRT) in India: a dandruff lotion and shampoo. It operates in two segments: pharmaceutical products, which generate the maximum revenue, and biotechnology.